Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?

Matthias M. Heck; Jürgen E. Gschwend

doi:10.1016/j.euf.2019.08.003

Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?

Matthias M. Heck, Jürgen E. Gschwend

Technical University of Munich

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

Although previous studies indicated a therapeutic benefit from superextended or extended lymph node dissection in bladder cancer patients undergoing radical cystectomy, the first prospective randomized trial could not confirm a significant survival benefit. With multimodal approaches including neoadjuvant or adjuvant chemotherapy as a gold standard, demonstrating any benefit may become even more difficult.

Original language	English
Pages (from-to)	617-619
Number of pages	3
Journal	European Urology Focus
Volume	6
Issue number	4
DOIs	https://doi.org/10.1016/j.euf.2019.08.003
State	Published - 15 Jul 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.euf.2019.08.003

Cite this

@article{614a0c8967ae4f648a93860fbf83f8c0,

title = "Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?",

abstract = "Although previous studies indicated a therapeutic benefit from superextended or extended lymph node dissection in bladder cancer patients undergoing radical cystectomy, the first prospective randomized trial could not confirm a significant survival benefit. With multimodal approaches including neoadjuvant or adjuvant chemotherapy as a gold standard, demonstrating any benefit may become even more difficult.",

author = "Heck, {Matthias M.} and Gschwend, {J{\"u}rgen E.}",

note = "Publisher Copyright: {\textcopyright} 2019 European Association of Urology",

year = "2020",

month = jul,

day = "15",

doi = "10.1016/j.euf.2019.08.003",

language = "English",

volume = "6",

pages = "617--619",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Extended Lymph Node Dissection for Bladder Cancer

T2 - Do Clinical Trials Rule Out a Benefit?

AU - Heck, Matthias M.

AU - Gschwend, Jürgen E.

PY - 2020/7/15

Y1 - 2020/7/15

N2 - Although previous studies indicated a therapeutic benefit from superextended or extended lymph node dissection in bladder cancer patients undergoing radical cystectomy, the first prospective randomized trial could not confirm a significant survival benefit. With multimodal approaches including neoadjuvant or adjuvant chemotherapy as a gold standard, demonstrating any benefit may become even more difficult.

AB - Although previous studies indicated a therapeutic benefit from superextended or extended lymph node dissection in bladder cancer patients undergoing radical cystectomy, the first prospective randomized trial could not confirm a significant survival benefit. With multimodal approaches including neoadjuvant or adjuvant chemotherapy as a gold standard, demonstrating any benefit may become even more difficult.

UR - http://www.scopus.com/inward/record.url?scp=85070670821&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.08.003

DO - 10.1016/j.euf.2019.08.003

M3 - Comment/debate

C2 - 31439506

AN - SCOPUS:85070670821

SN - 2405-4569

VL - 6

SP - 617

EP - 619

JO - European Urology Focus

JF - European Urology Focus

IS - 4

ER -

Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this